Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

Esposito, Katherine; Ciotola, Miryam; Carleo, Diego; Schisano, Bruno; Saccomanno, F.; Sasso, Ferdinando Carlo; Cozzolino, Domenico; Assaloni, Roberta; Merante, Domenico; Ceriello, Antonio; Giugliano, Dario

doi:10.2337/diacare.2951071

Cited by 55 publications

(44 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these association studies do not prove causality, and interventional studies using an effective treatment for OSA (such as CPAP) are needed to support this concept. The effect size of CPAP treatment on HOMA-IR is modest (20.44) when compared with the effect of the thiazolidinedione rosiglitazone, which has been reported to improve the HOMA-IR by 20.9 in nondiabetic obese patients or in those with the metabolic syndrome (34,35). Our study does not address whether OSA and the development of diabetes are causally linked.…”

Section: Original Articlementioning

confidence: 43%

Meta-analysis: Continuous Positive Airway Pressure Improves Insulin Resistance in Patients with Sleep Apnea without Diabetes

et al. 2013

View full text Add to dashboard Cite

Rationale: Obstructive sleep apnea (OSA) is an independent risk factor for the development of insulin resistance (IR). Treatment with continuous positive airway pressure (CPAP) for OSA has shown conflicting results on IR.Objectives: To conduct a meta-analysis of randomized controlled trials (RCTs) that have evaluated the effect of CPAP on a validated index of IR, the homeostasis model assessment of insulin resistance (HOMA-IR).Methods: PubMed and Embase were searched through August 10, 2012. Two independent reviewers screened citations to identify trials of the effect of CPAP on HOMA-IR. Data were extracted for postintervention HOMA-IR values. Measurements and Main Results:A total of five studies that enrolled 244 subjects (83% male) met the inclusion criteria. None of the subjects in the included studies had diabetes. The pooled estimate of the difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was 20.44 (95% confidence interval, 20.82 to 20.06; P = 0.02). The funnel plot does not suggest the presence of any publication bias. The I-squared index for the data on difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was 0.00 (P = 0.61). Conclusions:The pooled estimate of RCTs shows a favorable effect of CPAP on insulin resistance as measured by HOMA-IR in patients with OSA without diabetes. The effect size on HOMA-IR is modest, but not insignificant, when compared with the effects of thiazolidinedione in nondiabetic patients with metabolic syndrome. Further research and RCTs are warranted involving a larger number of patients and longer treatment periods to determine the beneficial effects of CPAP on IR.

show abstract

Section: Original Articlementioning

confidence: 43%

Meta-analysis: Continuous Positive Airway Pressure Improves Insulin Resistance in Patients with Sleep Apnea without Diabetes

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Up to now, limited studies have provided conflicting data about the influence of thiazolidinediones and prolonged exercise on human plasma adipocytokines (5,(15)(16)(17)(18)(19). We demonstrated that all interventions suppressed resistin and IL-6 levels, while both combined therapy and rosiglitazone treatment alone decreased TNF-␣ levels significantly.…”

Section: Kadoglou and Associatesmentioning

confidence: 71%

Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Kadoglou

Iliadis²,

Liapis³

et al. 2007

Diabetes Care

View full text Add to dashboard Cite

“…As noted above, RGZ improves the histological and biochemical changes in NAFLD along with the improvement in insulin resistance [9][10][11] . In addition, increased circulating levels of IL-18 are significantly decreased after RGZ therapy for patients with metabolic syndrome [33] or type 2 diabetes mellitus [34] . The present study showed that increased expression of IL-18 and caspase-1 in livers of NAFLD rats was reduced 4 wk after treatment with RGZ.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease

Wang¹,

Wang²,

Liu³

et al. 2008

WJG

View full text Add to dashboard Cite

AIM:To investigate the effects of rosiglitazone (RGZ) on expression of interleukin-18 (IL-18) and caspase-1 in liver of non-alcoholic fatty liver disease (NAFLD) rats. METHODS: Twenty-eight Sprague-Dawley (SD) rats were randomly divided into control, NAFLD, and RGZ treated NAFLD groups. A NAFLD rat model of NAFLD was established by feeding the animals with a high-fat diet for 12 wk. The NAFLD animals were treated with RGZ or vehicle for the last 4 wk (week 9-12) and then sacrificed to obtain liver tissues. Histological changes were analyzed with HE, oil red O and Masson's trichrome staining. Expressions of IL-18 and caspase-1 were detected using immunohistochemical staining and semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) analysis. RESULTS: The expression levels of both IL-18 and caspase-1 were higher in the liver of NAFLD group than in the control group. Steatosis, inflammation and fibrosis, found in the liver of NAFLD rats, were significantly improved 4 wk after RGZ treatment. The elevated hepatic IL-18 and caspase-1 expressions in NAFLD group were also significantly attenuated after RGZ treatment. CONCLUSION:RGZ treatment can ameliorate increased hepatic IL-18 production and histological changes in liver of NAFLD rats. The beneficial effects of RGZ on NAFLD may be partly due to its inhibitory effect on hepatic IL-18 production.

show abstract

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

Abstract: Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome.

Cited by 55 publications

References 39 publications

Meta-analysis: Continuous Positive Airway Pressure Improves Insulin Resistance in Patients with Sleep Apnea without Diabetes

Meta-analysis: Continuous Positive Airway Pressure Improves Insulin Resistance in Patients with Sleep Apnea without Diabetes

Beneficial Effects of Combined Treatment With Rosiglitazone and Exercise on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease

Contact Info

Product

Resources

About